SCHEMBL6316808

SCHEMBL6316808

COc1ccc(C(=O)Nc2onc(-c3ccsc3)c2C(N)=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.50
TP53 P04637 5/20 0.50
BACE1 P56817 1/20 0.46
FLT3 P36888 1/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA4 P22748 2/20 0.45
CA7 P43166 2/20 0.45
RAB9A P51151 7/20 0.45
NPC1 O15118 6/20 0.45
MAPT P10636 5/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323363 0.88 P2RY14 (0.47) SMN1; SMN2TP53FLT3RAB9ANPC1
SCHEMBL6315689 0.88 FLT3 (0.48) SMN1; SMN2TP53FLT3RAB9ANPC1
SCHEMBL6316752 0.87 IDO1 (0.42) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL6317590 0.86 SMN1; SMN2 (0.49) SMN1; SMN2TP53FLT3CA1CA2
SCHEMBL6321751 0.86 SMN1; SMN2 (0.53) SMN1; SMN2TP53FLT3CA1CA2
SCHEMBL6316805 0.86 CA1 (0.46) SMN1; SMN2TP53CA1CA2CA4
SCHEMBL6316187 0.85 KIT (0.46) SMN1; SMN2TP53FLT3CA1CA2
SCHEMBL6317604 0.85 DEGS1 (0.40) SMN1; SMN2TP53BACE1RAB9ANPC1
SCHEMBL6317801 0.85 RAB9A (0.50) SMN1; SMN2TP53BACE1RAB9ANPC1
SCHEMBL6316062 0.84 NPC1 (0.41) NPC1NPSR1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 SMN1; SMN2 2766/4885TP53 609/4885BACE1 895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.